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Abstract: Francisellosis in fish is caused by the facultative intracellular Gram-negative bacterial
pathogens Francisella noatunensis ssp. noatunensis and Francisella orientalis. The disease is affecting both
farmed and wild fish worldwide and no commercial vaccines are currently available. In this study,
we tested isolated membrane vesicles (MVs) as possible vaccine candidates based on previous trials
in zebrafish (Danio rerio) indicating promising vaccine efficacy. Here, the MV vaccine-candidates were
tested in their natural hosts, Atlantic cod (Gadus morhua L.) and Nile tilapia (Oreochromis niloticus).
Injection of MVs did not display any toxicity or other negative influence on the fish and gene
expression analysis indicated an influence on the host immune response. However, unlike in other
tested fish species, a protective immunity following vaccine application and immunization period
could not be detected in the Atlantic cod or tilapia. Further in vivo studies are required to achieve a
better understanding of the development of immunological memory in different fish species.
Keywords: francisellosis; vaccine; membrane vesicles; fish disease; Atlantic cod; tilapia
1. Introduction
Members of the Francisellaceae are Gram-negative, aerobic, facultative intracellular
cocco-bacilli with sizes ranging from 300 to 700 nm in diameter [1–4]. The francisella
species causes infection in a range of hosts. Most subspecies within Francisella tularensis
cause the disease tularemia, which can infect a number of mammals, including humans [5].
Other Francisella species, F. noatunensis ssp. noatunensis (Fnn), F. noatunensis ssp. chilensis
and F. orientalis (Fo) (previously F. noatunensis ssp. orientalis) are adapted to the aquatic
environment. Fnn and Fo cause francisellosis, a systemic infection in both farmed and wild
fish living in cold or warm water, respectively [6–12].
Francisella infections in fish are mainly characterized by macroscopically visible gran-
uloma on gills and skin as well as formation of internal granulomas, usually prominent
in spleen, heart, kidney and liver [2,8,13]. Early reports of francisellosis caused by Fnn
were registered after several Norwegian Atlantic cod (Gadus morhua L.) farms experienced
losses of up to 40% between July and August 2005. The infection was described as a severe
granulomatous inflammatory disease [2,3]. Systematic granulomatous conditions had been
previously reported in cultured Nile tilapia (Oreochromis niloticus) (further referred to as
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tilapia) in Taiwan, Hawaii and the continental United States [6,14–16]. It was, however,
only confirmed in 2007 that the Fo species was the causative agent of these outbreaks [17].
Infections in tilapia with Fo display a high mortality rate, whereas infection in Atlantic cod
with Fnn is characterized as a chronic infection [13].
To date, there is no efficient vaccine against francisellosis available on the market.
Vaccine trials using whole-cell inactivated bacteria with or without different oil adjuvants
displayed only limited protection [18–20]. Attenuated live vaccines have demonstrated
protection, but may be subject to licensing difficulties due to possible reversion back
to virulence [21–24].
An alternative vaccine approach is the use of extracellular membrane vesicles (MVs)
secreted by the bacteria [25–27]. The spherical MVs are 10–300 nm in diameter and contain
different proteins, DNA, RNA and virulence factors and are thereby representing the
mother cell in a nonreplicative form [27,28]. Vaccination with MVs has previously been
shown to provide protection in a range of species [29,30]. In fish, MV immunization has
provided protection against, i.e., edwardsiellosis infection in olive flounder (Paralichthys
olivaceus) [31]. Moreover, immunization experiments against francisellosis using isolated
MVs showed promising results towards protective immunity against Fnn [26] and Fo [27]
in an adult zebrafish (Danio rerio) model. The immunization with Fo MVs induced an
antibody response in zebrafish and infection challenge of vaccinated zebrafish displayed a
65.5% survival rate [27]. Considering the nonlethal chronic infection characteristics of Fnn,
the vaccine derived from Fnn MVs, induced protection against subsequent Fnn infection in
zebrafish [26]. Due to the protective effect of the MV immunization observed in zebrafish
against infection from Fnn and Fo, in the current study the immunization properties of
isolated MVs were tested in their natural hosts, the Atlantic cod and tilapia, respectively.
2. Materials and Methods
2.1. Bacteria, Media and Growth Conditions
Fnn strain NCIMB14265T was isolated from diseased Atlantic cod in Norway [2].
Fo strain 07-285A was an isolate from diseased tilapia in Costa Rica [32]. Cultivation
was performed on ECA plates consisting of 30.4 g/L BD Bacto™ Eugon Broth (Difco
Laboratories, US) supplemented with 15 g/L Microbiology Agar (Merck) and 5% bovine
blood (Håtunlab AB) or in Eugon Broth (BD BactoTM Eugon Broth, Difco Laboratories, US)
supplemented with 2 mM FeCl3 (Sigma-Aldrich, Saint Louis, MO, USA) with agitation (100
rpm) at 20 ◦C as previously described in [33,34]. Bacterial stocks were frozen in autoclaved
10% skimmed milk (Difco, Sparks, US) or in Bacto Eugon broth supplemented with 20%
glycerol (Sigma-Aldrich, Saint Louis, MO, USA) and stored at −80 ◦C.
2.2. Isolation of Membrane Vesicles
Fnn and Fo MVs were produced in batch fermentation (3-L Applikon fermenters) at
20 ◦C in BD Bacto™ Eugon Broth (Difco Laboratories, Franklin Lakes, NJ, USA) supple-
mented with 2 mM FeCl3 (Sigma-Aldrich, Saint Louis, MO, USA), and pH was retained
at 7.0. Dissolved oxygen was maintained at 20% with a flow of 15–24 VVh and stirring.
The culture was inoculated at OD600 of 0.1 and harvested at OD600 of 4.0. The culture was
centrifuged and the cell free supernatant was stored at−80 ◦C awaiting further purification
of MVs. The frozen ferment was thawed and sterile filtered (0.2 µm, Nalgene Rapid-Flow
Sterile Disposable Filter Units with PES Membrane, Cat. No: 124-0045, Thermo Fisher,
Waltham, MA, USA) prior to further processing. Tangential flow filtration was used under
sterile conditions to concentrate the MVs. The pump rate for filtration was 30–50 ml reten-
tate/min at a premembrane pressure of 1.0–1.8 bars. Three membranes (Pellicon XL 50 cm2
Microfiltration Cassettes, Merck Millipore, Burlington, MA, USA) with cut-offs of 10 kDa
were connected in parallel. The retentate (including MVs) was recirculated for ~3 h by recir-
culating the retentate flow to the feed solution. The concentrated fermentate was stored at
4 ◦C until ultracentrifugation (Sorvall 80 MX, (Thermo Scientific, Waltham, MA, USA) with
a fixed angle rotor T-865, average 110,000× g, 2 h, 20 ◦C). The supernatant was decanted
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immediately after centrifugation, and the pellet was washed two times with hydroxyethyl
piperazineethanesulfonic acid (HEPES) buffer (50 mM, pH 6.8, Sigma-Aldrich, Saint Louis,
MO, USA) and centrifuged (110,000× g, 1 h, 20 ◦C). The pelleted MVs were suspended in
Phosphate Buffered Saline (PBS) solution. A small volume of purified MVs was spread
on ECA plates (see Section 2.1) and Luria-Bertani (LB) agar plates (LB broth with agar,
Sigma-Aldrich, Saint Louis, MO, USA) to ensure sterility. The protein concentration was
measured with a Qubit 2.0 Fluorometer (Invitrogen by Life Technologies, San Diego, CA,
USA) and used as an indirect estimate of MV concentration. MVs were frozen at −80 ◦C
before use in vaccination trials.
2.3. Toxicity, Immunization and Challenge Trial in Tilapia
The toxicity of different concentrations of MVs was assessed in a pilot toxicity trial in
tilapia. All experiments in tilapia were performed at the Norwegian University of Life Sci-
ences, following the regulations controlling experiments with live animals in Norway and
approved by the Norwegian Food Safety Authority, Oslo, Norway (FOTS ID 6966/7026).
The experimental fish were held in recirculating aquaculture systems (RAS) in 250 L tanks
(32 fish), at a water temperature of 25 ◦C, pH 7.4 with dissolved oxygen at least 5.4 mg/L or
better; the experimental animals were fed daily (Aller Aqua, Christiansfeld, Denmark) at a
rate of 2% bodyweight according to standard protocols as described in Soto et al. 2013 [10].
The fish were incubated with 12 h light and 12 h dark photoperiods and were monitored
daily. Experiments were conducted on randomly chosen animals of both gender at an aver-
age weight of 25 g (fish were bulked weight); animals were marked with Radio Frequency
Identification (RFID) tags (also called Passive integrated transponder (PIT) tags) [35].
The trial included four test groups, each consisting of eight fish. The different test
groups were intraperitoneal (IP) injected with 100 µL physiological saline solution con-
taining either 40 or 400 µg of MVs from Fo or physiological saline alone. One test group
served as control where the fish remained untreated. Fourteen days after injection all
fish were euthanized with 0.03 mg/L Benzoak® 200 mg/mL (ACD Pharmaceuticals AS,
Leknes, Norway). Gene expression levels were evaluated using harvested spleen tissue
for quantitative PCR (qPCR) analysis. Additionally, serum samples were taken to evaluate
Fo specific immunoglobulin (IgM) antibody level, using enzyme-linked immunosorbent
assay (ELISA).
For the MV immunization trial in tilapia, an IP injection of 40 µg of MV suspended in
100 µL PBS, isolated from Fo, was administered. The fish had an average start weight of
25 g and were held and fed under the same conditions as described above for the toxicity
experiment. The four experimental groups with 36 tilapia in each group were kept in
perforated metal baskets with metal nets (pore size 2 mm) in the same 250 L glass fiber tank.
The four experimental groups consisted of a MV vaccinated group injected with 100 µL of
40 µg of Fo MVs emulsified in the adjuvant Montanide ISA 761 VG; L10415 (Seppic), an
adjuvant group, a placebo group (injected with 100 µL physiological saline) and a control
group (did not receive any treatment). Each of the experimental groups consisted of 36 fish.
After vaccination, the fish were held for 24 days (600 degree/days) to allow development of
specific immunity. Following the immunization period, fish were subjected to cohabitation
challenge with disease carriers (shedders; 29 fish) that were inoculated intraperitoneally
with 100 µL of Fo (3× 105 CFU/mL) and kept in a separate tank of 250 L that was connected
to the experimental tank with a recirculating pump introducing the Fo pathogen into the
rearing water. Mortality was monitored for 61 days. For evaluation of immune response
parameters, spleen and head kidney tissues were collected and used for qPCR analysis.
Head kidney, heart and muscle tissues from survivors were collected after 61 days for later
evaluation of bacterial burden by qPCR.
2.4. Toxicity, Immunization and Challenge in Atlantic Cod
All experiments in Atlantic cod were performed at Tromsø research station, Kårvika,
following the regulations controlling experiments with live animals in Norway and ap-
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proved by the Norwegian Food Safety Authority (FOTS ID 8171/8172). To exclude potential
harmfulness of different concentrations of MVs isolated from Fnn, a toxicity trial was per-
formed. The experimental groups were held together in one 300 L tank (32 fish). The
fish were of mixed gender and were marked with RFID tags. During the duration of the
experiments, the fish were maintained at 12 ◦C water temperature with fresh flow through
marine water (1.5 L/kg/min) and dissolved oxygen was 8.0 mg/L or better. The fish were
exposed to 12 h of artificial light and fed twice a day with dry pellets at a rate of 1% of
the body weight (start weight 30 g). Two different doses of Fnn MVs (40 and 400 µg) were
administered to two groups of fish by a single IP injection dissolved in 100 µL of physio-
logical saline solution. Additionally, a placebo group (injected with 100 µL of physiological
saline) and a control group (did not receive any treatment) were included in the toxicity
trial. Each experimental group consisted of 8 fish. After 14 days, the fish were euthanized
using a two-stage procedure suitable for fish with anesthesia using 0.03 mg/L Benzoak®
200 mg/mL (ACD Pharmaceuticals AS, Leknes, Norway) followed by a sharp blow to the
head. Spleen tissues from all groups were harvested and immune gene expression levels
were evaluated using qPCR.
For the MV immunization trial in Atlantic cod, the fish were kept under the same
conditions as described above and had a starting weight of 30 g (fish were bulk weight).
The size of the tank the fish were kept in was 1800 L. All groups were held together in one
tank (312 fish). Fish were randomly put into 4 groups of 65 individuals; each individual
from the vaccine group received a single IP injection of 100 µL solution containing 40 µg
MV conjugated with Montanide ISA 761 VG L10415 (Seppic) adjuvant. Individuals from
the adjuvant group received an injection with Montanide ISA 761 VG L10415 only. Fish
from the placebo group received a single IP injection of 100 µL of physiological saline.
The fourth group was an untreated control group. Fifty days after injection, the fish were
challenged using a cohabitation model using shedder fish (40 individuals), to allow natural
disease transmittance between the groups. Shedders were inoculated by IP injection of the
pathogen (3.0 × 107 CFU/mL). The fish were observed for around 8 weeks (61 days) and
random fish of each group were euthanized at the set time-point of 30 days postchallenge
(dpc) (12 fish per group) and 61 dpc (24 fish per group) for sampling of head kidney, spleen
and serum for experimental evaluation of immune gene expression level using qPCR.
2.5. Bacteriology
The liver and a block of tissue of randomly selected tilapia were aseptically collected
and homogenized with steel beads in 500 µL of sterile 1% NaCl for 20 s to disrupt tissues.
The suspension was briefly spun in a microcentrifuge and plated on Eugon Chocolate Agar
(BD). Plates were incubated at 20 ◦C and observed for colonies. Colonies were verified
with Gram staining (data not shown).
2.6. RNA Isolation and Quantitative Real-Time PCR
Tissues harvested for RNA isolation were stored in RNAlater (Ambion, Life Technolo-
gies, Carlsbad, CA, US) at −20 ◦C until further processing. Total RNA was extracted using
the RNeasy kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions.
Tissues were homogenized in 600 µL of RLT buffer (supplemented in RNeasy Plus Mini Kit,
Qiagen) using glass beads (Sigma Aldrich) and homogenizer Precellys 24 (Bertin Technolo-
gies, Minilys, Montigny le Bretonneux, France). RNA was eluted in 30 µL RNAse-free H2O
(Qiagen). RNA was quantified using a Nanodrop UV5Nano (Mettler Toledo, Greifensee,
Switzerland). Reverse transcription was performed using a High Capacity RNA to cDNA
kit (Applied Biosystems, Thermo Scientific, Vilnius, Lithuania) following the manufac-
turer’s protocol. Gene expression levels were analyzed via qPCR using a CFX89 lightcycler
(Bio-Rad, Singapore). The reaction was carried out using either LightCycler®480 SYBR
Green I Master (Roche, Indianapolis, IN, US) or iTaq Universal SYBR Green Supermix
(Bio-Rad, US), cDNA was diluted to 1:10 and the final reaction volume was 10 µL. Primers
used are listed in Table A1 and qPCR was performed at 62 ◦C annealing temperature and
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40 cycles. Relative expression (∆∆Ct) was calculated either using Bio-Rad CFX Maestro
software or the spreadsheet from Vandesompele et al. [36]. Gene expression was normal-
ized against one or two reference genes, respectively (β-actin in tilapia; ef1α and ubiquitin
(Ubi) in Atlantic cod), whose stability was tested with the Bio-Rad CFX Maestro software.
For Atlantic cod the following immune marker genes were measured: il1β, il6, il8, il10,
infγ, igm-lc, igm-hc, while for tilapia il1β, tnfα, cd83, igm, infγ, il12, cox2, mhcII, igd immune
marker genes were measured. All immune marker genes were tested for both the MV
toxicity and the MV vaccination trial. Genes that did not display any detectable expression
level were not included in the figures.
2.7. Serum Collection and ELISA
Serum samples from tilapia were collected from eight fish at the end of the toxicity
trial. In the case of Atlantic cod, serum samples were collected from three fish from both
the toxicity assay and from three fish from each group in the vaccine trial at the time-
points 0, 30 and 61 dpc. Enzyme-linked immunosorbent assay (ELISA) was performed
using an anti-Tilapia (Oreochromis niloticus) IgM monoclonal antibody (Aquatic Diagnostics
Ltd., Stirling, Scotland) and anti-Cod (G. morhua L)/Haddock (Melanogrammus aeglefinus)
IgM monoclonal antibody (Aquatic Diagnostics Ltd., Stirling, Scotland), following the
manufacturer’s protocol.
2.8. Quantification of Bacterial Burden in Tilapia
The presence of bacterial genomic DNA (gDNA) in heart, head kidney and muscle
tissues was evaluated using a primer pair specific for Fo [37] (Table A1). Sampled tissue was
transferred to RNAlater (Ambion) and stored at 4 ◦C. Extraction of gDNA was performed
with the DNeasy Blood and Tissue Kit (Qiagen) according to the manufacturer’s protocol;
qPCR was performed with a volume of 20 µL and Fo gDNA was used as standard for the
qPCR plate.
2.9. Statistical Analysis
Statistical analyses were performed using GraphPad Prism software version 8. The
data were checked for normal distribution (Shapiro–Wilk Normality test) and outliers were
identified and removed using robust regression and outlier removal (ROUT) (Q = 1%). The
assumption of equal variances (i.e., assumption of homoscedasticity) was tested using the
Brown–Forsythe test and, if needed, the data were log-transformed to meet the test criteria.
Statistically relevant differences in gene expression among treatments were assessed by
one-way ANOVA, followed by a Tukey multiple comparison test. The survival curve was
generated using the Kaplan–Meier method.
3. Results
3.1. Fo MV Toxicity and Immunization Trial in Tilapia
3.1.1. High Concentration of Fo MVs Are Not Toxic and Elicit a Limited Immune Response
in Tilapia
Before initiating the MV vaccine trial in tilapia, the toxicity of two different doses
of MVs were tested. The 40 µg dose was chosen based on previous concentrations of
MV used in immunization experiments in fish and mammals [27,31,38,39]. In addition,
a ten times higher dose of 400 µg was used. Tilapia did not display any clinical signs
or toxic reaction to either a low (40 µg) or high (400 µg) dose of injected MVs. During
dissection, no macroscopically visible pathological effects were observed in the internal
organs in response to the IP injection. To further evaluate differences in immune responses
to different MV concentrations, gene expression levels were measured for a selection of
immune-related genes (il1β, tnfα, cd83, igm, il12, infγ, cox2, mhcII).
Two genes, il1β and tnfα, were significantly upregulated in response to injection
with 400 µg of Fo MVs and, interestingly, the significant upregulation of tnfα was not
significant compared to the saline-treated group (Figure 1A). Surprisingly, transcription of
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infγ, il12 and mhcII were upregulated in response to the saline injection, which functioned
as a placebo treatment. For cd83 and igm, significant differences in expression were only
detected in the control and the saline-treated fish. No significant changes in cox2 gene
expression level in response to the IP injections were detected. No significant increase in
abundance of IgM specific antibodies was identified following ELISA of serum samples
from fish in the toxicity trial (Figure 1B).




Figure 1. Immune responses in tilapia 14 days after injection of 40 or 400 µg of Fo membrane vesicles (MVs) compared to 
saline-injected or untreated fish. (A) Log2 of relative mRNA abundance of a selection of immune genes performed by 
qPCR on isolated spleen from eight fish per group. (B) Enzyme-linked immunosorbent assay (ELISA) measuring specific 
IgM against Fo. Absorbance was measured at 450 nm. Labelling with different letters (a; b) indicates significant differences 
between groups; groups that do not share letters are significantly different. The absence of letters indicates a lack of sig-
nificant differences (p < 0.05; one-way ANOVA with multiple comparisons using Tukey test; error bars indicate mean ± 
SEM (standard error of the mean)). Note that the scale on Y-axis can differ in (A). 
3.1.2. MV Immunization Did Not Protect Tilapia From Fo Infection 
After establishing that Fo MVs did not give rise to any toxic effect, an immunization 
and challenge experiment was set up with the Fo MVs in tilapia. Although a limited im-
mune response in the fish from the toxicity experiment was observed for the high (400 µg) 
dose, the dose of 40 µg Fo MVs was chosen for the vaccine experiment. To compensate for 
Figure 1. Immune responses in tilapia 14 days after injection of 40 or 400 µg of Fo membrane vesicles (MVs) compared
to saline-injected or untreated fish. (A) Log2 of relative mRNA abundance of a selection of immune genes performed
by qPCR on isolated spleen from eight fish per group. (B) Enzyme-linked immunosorbent assay (ELISA) measuring
specific IgM against Fo. Absorbance was measured at 450 nm. Labelling with different letters (a; b) indicates significant
differences between groups; groups that do not share letters are significantly different. The absence of letters indicates a
lack of si nificant differences (p < 0.05; one-way ANOVA with multiple comparisons using Tuk y test; error bars indicate
mean ± SEM (standard error f the mean)). Note that the scale on Y- xis can d ffer in (A).
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3.1.2. MV Immunization Did Not Protect Tilapia From Fo Infection
After establishing that Fo MVs did not give rise to any toxic effect, an immunization
and challenge experiment was set up with the Fo MVs in tilapia. Although a limited
immune response in the fish from the toxicity experiment was observed for the high (400 µg)
dose, the dose of 40 µg Fo MVs was chosen for the vaccine experiment. To compensate for a
reduced immune response and due to the fact that many commercial vaccine formulations
include an adjuvant, the Fo MVs were mixed with an adjuvant before immunization.
Surprisingly, no differences in survival were detected between the different groups, whether
they were immunized with the MV formulation or not (Figure 2A). Aligned with these
results is the observation that no significant differences in expression levels of the immune
marker genes could be detected between any of the groups in the immunization trial
(Figure 1A).
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Figure 2. Survival and bacterial burden of adult tilapia immunized with Fo MVs and subsequently
challenged with Fo. (A) Kaplan–Meier curve of cumulative s rvival (%) of tilapia immunized with
40 µg Fo MVs, injected with adjuvant or a saline solution, or left untreated after a cohabitation
ch llenge with shedders injected with 3 × 105 CFU/mL of Fo. (B) Graphic represents median log2 of
Fo co tent in heart, muscle and kidne ti s collected during vaccine trial. The bacterial burden
was detected by qPCR of genomic DNA isolated from the respective tis ues. Different letters (a; b)
indicate significant differences; groups that do not share letters are significantly different. The
absence of letters indicates a lack of ignificant differences (p < 0.05; one-way ANOVA with multiple
comparisons using Tukey test; error bars indicate mean ± SEM).
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The bacterial burden between the various groups was then measured using gDNA,
isolated from the euthanized fish (Figure 2B). In heart and kidney tissues, the detected Fo
content was similar for all four groups. In the muscle tissue, however, a significant increase
in Fo content was detected in the saline group compared to the control and vaccine groups,
but not to the adjuvant, which was not statistically different from vaccine and control.
3.2. Fnn MV Toxicity and Immunization Trial in Atlantic Cod
High concentrations of Fnn MVs are not toxic and do not induce significant immune
response in Atlantic cod.
When injecting Atlantic cod with either the 40 or 400 µg dose of MVs, none of the fish
showed any clinical signs or toxicity reaction. These results are similar to those observed in
tilapia. To further evaluate the potential immune responses to the MVs in the fish, gene
expression levels were monitored for a selection of immune regulating genes between the
different test groups (igm hc, igm lc, il1β, il6, il8, infγ, il10) (Figure A2). Interestingly, none
of the investigated genes showed any significant up- or downregulation in response to the
different concentrations of injected MVs or the saline injection.
Immunization with MVs Did Not Induce Immunity against Fnn Infection
Similar to tilapia, Atlantic cod was immunized with a dose of 40 µg of Fnn MVs during
the immunization and challenge trial. Also similar to tilapia, an adjuvant was used to boost
the lack of immune response observed during the toxicity trial. Throughout the duration
of the vaccine trial, both during the immunization and the challenge period, only three
fish from different groups died. This fits the characterization of francisellosis as a chronic
disease in Atlantic cod [13]. During sampling at 30 dpc, however, typical signs of infection
were observed. Fish from all groups had macroscopically visible granuloma in the liver,
which could in some cases also be seen on the spleen and kidney. Most of the fish had
pale hearts and gills and enlarged spleens and kidneys. In some fish, a congested liver
was observed in addition to the granuloma. Additionally, in some of the vaccinated and
adjuvant-treated fish, fusions between liver and muscle tissues in the intraperitoneal cavity
were observed.
A selection of immune genes that were found to be expressed in Atlantic cod samples
(igm, il1β, il8, infγ, il10) was used for the analysis of immune responses by qPCR from
both kidney and spleen harvested at 30 and 61 dpc. The primary immune response,
detected in form of igm expression, showed significant upregulation in the adjuvant-
treated group compared to the control and vaccine groups—30 dpc in the spleen tissue
(Figure 3). Compared to the gene expression level of igm at 30 dpc, the shedder group
showed an upregulation after 61 dpc, whereas the other groups seemed to have the same
expression level. In the head kidney, igm expression was upregulated in the shedder group
at 30 dpc and, interestingly, igm expression at 61 dpc was significantly downregulated in
the adjuvant- and saline-treated groups compared to the control group. The expression of
the proinflammatory cytokine il1β was constantly significantly higher in the shedder group
at the different time-points in the two different tissues—a trend also observed for il8, infγ
and il10. At 61 dpc in the kidney, il8 was downregulated in the adjuvant- and especially in
the saline-treated groups in comparison to the control and vaccinated groups. The same
downregulation of gene expression was observed for infγ in the kidney of the saline-treated
group at 61 dpc. In the case of il10, expression was only detected in the spleen and kidney
samples that were taken at 30 dpc, following the general detected trend of higher gene
expression in the shedder group, at least in the spleen tissue. In the head kidney, there
were no significant differences between the different groups for the expression level of il10.
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Figure 3. Immune gene expression levels in Atlantic cod immunized with Fnn MVs and challenged with Fnn. Sample
analysis was performed by qPCR on the spleen and kidney at two time-points—30 and 61 dpc. The relative gene expression
of different investigated genes displayed as log2 of relative mRNA abundance. Results marked with different letters (a; b)
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3.3. Increased IgM level in Fnn Immunized Atlantic Cod before and 30 Days Postchallenge
No difference in IgM against Fnn could be detected in any of the groups during the
MV toxicity trial in Atlantic cod (Figure 4). These samples were harvested only 14 days
after immunizations and could be the reason for this lack of immune response in the fish.
An increased abundance of IgM specific against Fnn could be detected in samples from the
immunized group injected with 40 µg of MVs 50 days after immunization compared to the
nonimmunized groups and the group injected only with adjuvant. The same observations
were made at 30 dpc. At days 0 and at 30 dpc, the antibody levels of vaccinated fish were
significantly higher than the antibody levels in all of the groups at 61 dpc.
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Figure 4. Detection of anti-Fnn IgM in the serum of Atlantic cod immunized with Fnn MVs assayed by ELISA in both
the toxicity and vaccine trials. In the toxicity trial, the fish were immunized with either 40 or 400 µg of Fnn MVs. In the
vaccine trial, the fish were immunized with either 40 µg of Fnn MVs mixed with an adjuvant or with adjuvant alone. In both
trials, a saline-injected group was included in addition to an untreated group (control). In the toxicity trial, the serum was
collected 14 days after Fnn MV injection. Serum samples were obtained from three fish from each respective group at given
time-points during the vaccine experiment. Results marked with different letters (a; b) show the significant difference;
groups that do not share letters are significantly different (p < 0.05; one-way ANOVA with multiple comparison using Tukey
test; error bars indicate mean ± SEM).
4. Discussion
Francisellosis caused by Fnn and Fo has emerged to a worldwide problem in fish
farms and efforts have been made to find an effective vaccine. The vaccine candidates
tested in this study are isolated MVs from Fnn and Fo, as MV vaccines against francisellosis
showed promising results when previously tested in an adult zebrafish model [26,27].
It was therefore of interest to investigate the possible vaccine application of isolated MVs
in the natural hosts of Fnn and Fo, the Atlantic cod and tilapia, respectively. Interestingly,
but unfortunately, a protective immunity could not be observed in the natural hosts, the
Atlan ic cod and tilapia, when the fish were immunize with MVs isolated from Fnn or
Fo. When initially testing the potential toxicity of the MVs in the fish, an interesting result
in tilapia was the upregulation of the proinflammatory cytokine il1β in the spleen of fish
injected with 400 µg of MVs. This upregulation resembles the immune response seen in
the actual bacterial infection [40,41]. This could indicate that the acellular MVs can initiate
an immune reaction in tilapia, as previously shown in zebrafish [27]. In comparison to
this, infγ was only significantly upregulated in saline-treated tissue, whereas in zebrafish
injected with Fo MVs, it was significantly upregulated [27]. This could be an indication of
the different effects of MVs on gene expression in its natural host and the model fish. It was
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previously shown that Francisella ssp. have immune-suppressive influences and interfere
with infγ signaling. It is proposed that Francisella ssp. target the infγ signaling pathway by
preventing of downstream activation of transcription factors [42,43]. LC-MS/MS analysis
of the MV content of Fo showed an abundance of important virulence factors, such as IglC
(a protein necessary for intracellular growth and escape from phagolysosomes), chaperon
proteins associated with immunogenic effects and cytoplasmic proteins. This cargo could
be sufficient to influence the host immune response [27]. Another observation was that
mhcII, infγ and il12 are significantly upregulated in the saline-treated group compared
to the control group. In a different study that used an inactivated whole-cell vaccine, an
upregulation of mhcII expression level was observed after vaccination, which was associ-
ated with the successful recognition of the Fo cells [44]. In the case of the injected Fo MVs,
the upregulation of the proinflammatory cytokines but not mhcII, infγ or il12 expression,
which are only upregulated in the saline-treated group, supports the assumption that MVs
are capable of active manipulation of the immune response in a similar fashion to natural
infections. Further supporting this theory, igm gene expression is only upregulated in the
saline-treated group compared to the control group. Upregulation of igm gene expression
and the detection of Fo specific IgM in serum samples was reported in a previous study
and is associated with B-cell activation which is involved in development of a protective
immune response [44]. In zebrafish, igm expression was also significantly upregulated
7 days post vaccination with Fo MVs [27]. The immune response of zebrafish, used as a
model organism, and tilapia, the natural host, might of course differ. In accordance with
the lack of induction of igm mRNA in the spleen, no significant amount of IgM antibody
against Fo was found in the tilapia serum. The expression level of the B-cell marker cd83
is, as igm, only upregulated in the saline-treated group compared to the control group.
When looking at differences in response to the two different doses of Fo MV, only the
significant upregulation of the genes coding for the proinflammatory cytokine il1β was
detected. Generally, there do not seem to be any further detectable differences in gene
expression levels in response to the different dosages of immunization with the MVs. These
data indicate that the injected Fo MVs do not have any toxic effect on tilapia and that the
cargo of the MVs might have the ability to actively influence the immune response in this
fish species.
The general upregulation of genes in the saline-treated group leads to the assumption
that the IP injection itself also triggers an immune response. It is a forced invasion into the
fish body and the penetration through skin and tissue into the intraperitoneal cave could
enable other pathogens to enter. However, the IP injections were performed under aseptic
conditions so that the increased expression levels occur most likely as an immune response
to the stress induced by anaesthesia, handling and injection of saline. Usually, the saline-
treated group serves as the control group, but we included a control group without any
treatment in our experiments. This control group enabled detection of the upregulations
in the saline-treated group, indicating a possible effect on the immune response being
triggered by the IP injection alone.
Previous trials with MVs of Gram-negative bacteria as vaccine candidates showed
promising results—i.e., against edwardsiellosis in olive flounder (Paralichthys olivaceus)
or against infection with Flavobacterium psychrophilum in rainbow trout (Oncorhynchus
mykiss) [31,45]. In this study, tilapia were vaccinated with 40 µg of Fo MVs and the fish
were kept for 24 days, in order to develop specific immunity, before they were challenged
by Fo infection. The survival rate displayed no significant difference between the different
groups and there was no vaccine efficacy detectable. Within vaccinated groups, qPCR
analysis did not reveal any significant up- or downregulation of any of the tested immune
genes. This might be due to the sampling time-point, which was after the trial at 61 dpc,
where possible changes in expression levels were most likely not detectable. For future
trials, several and earlier sampling time-points are eligible, such as, i.e., sample points for
zebrafish, or in tilapia [27,44]. Significant differences in bacterial load were only detected
in the muscle tissues of the different groups. The control and the vaccinated groups had a
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significantly lower bacterial load than the saline-treated group, which may be an indication
for an impaired innate immune system in the vaccinated group, caused by the reaction
in response to the vaccine injection, and that no immunity was formed to the sampling
time-point. Similarly, it was expected that the bacterial burden would be similar in the
control group and the group of fish injected with saline solution. This result aligns with the
observation that the MVs might not induce the development of protective immunity against
Fo infection in tilapia. The MVs seem to interfere and manipulate the host immune system
similar to the pattern of the bacteria itself, by upregulation of certain proinflammatory
cytokines and prevention of downstream transcription factor activation [34,42–44,46–49].
Besides this, an adjuvant was used in combination with the MVs. Thus, it cannot be ruled
out that the adjuvant did not have the expected effect of enhancing an immune response
and development of specific immunity together with the MVs, but rather the opposite.
The group treated only with adjuvant did not display an elevated immune response nor
improved immunity against the infection compared with the MV-treated group, suggesting
no beneficial effect of using an adjuvant.
In contrast to the toxicity trial in tilapia, the results from the toxicity trial in Atlantic
cod with Fnn MVs showed no significant up- or downregulation in any of the tested
genes. It is possible that the sampling point 14 days after injection would not reveal any
specific immune response, neither early nor late, respectively. The sampling could have
been performed earlier or the experiment should have been continued longer. In any case,
several sampling points would be preferable in order to detect comprehensive changes in
the gene expression levels.
Francisellosis in Atlantic cod is characterized as a chronical, nonlethal infection [13]
and during the time-span of the vaccine trial, no disease-related mortalities were detected.
However, observations during sampling of the fish at 30 dpc described typical signs of
francisellosis infection. The described granuloma on liver, spleen and kidney tissues in
addition to occasionally observed enlargement of spleen and kidney, in fish from all groups,
indicate that the MVs used as a vaccine were not able to prevent Fnn from infecting the
vaccinated fish. Additionally, in some of the vaccinated and adjuvant-treated fish, fusions
between liver and muscle tissues in the intraperitoneal cavity were observed. The fusions
are likely a result of the IP injection which was either unfortunately placed or the adjuvant
might have negatively interfered with the tissue and induced the formation of lesions [50].
Samples collected from shedder fish were included in the analysis for this trial and
provided an interesting comparison. When analyzing the immune gene expression of both
spleen and kidney, only il1β was significantly upregulated in the shedder group compared
to the control, except for 30 dpc in the kidney. This gene regulation of il1β expression
levels resembled the known immune response pattern to Fnn infection [40,51]. The fact
that it is not upregulated in any of the other groups is, however, surprising since one
would expect the other fish in the tank to be infected with francisellosis at the sampling
time-points. infγ expression levels are upregulated in the shedder’s spleen; however, from
viewing previously described expression levels of infγ during infection in Atlantic cod,
one would rather expect it to be downregulated [42,43,51]. The expression level of igm
varies in-between sampling time-points and tissue. The upregulation of igm in the adjuvant
group at 30 dpc in the spleen, compared to the vaccinated and control group, displays the
desired effect of the adjuvant—i.e., to enhance an immune defense. At 30 dpc in the kidney,
igm was upregulated in the shedder group compared to the vaccine, adjuvant and saline
groups. This might be due to the long exposure and infection times in the shedders, which
were directly injected with the pathogen. At 61 dpc in the spleen sample, an increased
igm level was detected in the shedders, compared to all other groups. This might be
due to the direct infection dose injected into the shedders. In comparison to this, igm is
significantly upregulated in the control group in the kidney at 61 dpc and seems therefore
downregulated in the adjuvant- and saline-treated groups. More sampling time-points
are important in order to trace changes in gene expression comprehensively. To the two
time-points of the vaccine trial, another sampling before the challenge would be preferable.
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IgM levels in serum samples were only significantly upregulated in the vaccinated group
before the challenge and at 30 dpc in comparison to all samples at 61 dpc. Interpreting
these results as an indication for induced immune response in response to the vaccine
seems bold as there is no significant difference to the other samples. However, the early
increase in specific IgM levels resembles results from a current MV trial in salmon (Salmo
salar) where an early short-term immunization could be observed (data not published).
Taken together, there are few indications that vaccination at a dose of 40 µg of Fnn
or Fo MVs induces protection against francisellosis. The immunized fish were not found
to reveal any significantly improved immune response towards the challenge with these
two infectious agents. The macroscopic observations made during sampling, however,
led to the belief that there would not have been a detectable difference. A higher dose
of MVs could induce an immune response that would lead to protective immunity. The
doses applied in this study were, however, the same as previously used in zebrafish [26].
Other studies using isolated pathogen MVs in fish and mammals showed induction of
immunity with even lower injection doses (5–20 µg of MV concentration) [27,31,38,39].
This indicates that the applied MV doses should be evaluated for the respective pathogen
they are being isolated from. However, viewing the results of the MV injection in tilapia,
the effect of a higher MV dose might only lead to suppression and manipulation of the
immune system rather than inducing the development of immunity. The immune system
of Atlantic cod in itself is quite unique, considering the lack of genes coding for mhcii and
needed components for its expression and transportation [52]. The diversity in the immune
system between Atlantic cod and tilapia might account for differential gene expression in
response to MV injection.
It would be an interesting experimental setup to test many different concentrations
of MVs in both Atlantic cod and tilapia and further evaluate and compare the impact on
the immune response. A different immunization approach could involve mixing of the
MVs with inactivated bacteria, as has been performed for Flavobacterium psychrophilum in
rainbow trout (Oncorhynchus mykiss) [45]. As mentioned before, more sampling time-points
and a longer immunization phase should be considered. Immune studies in carp (Cyprinus
carpio) suggested that formation of optimal immunological memory is reached only after
three to eight months and Ye et al. (2013) suggested that, for the development of successful
vaccines in fish, more studies on development of long-term memory are required [53,54].
5. Conclusions
The interesting finding in this study is that no protective immunity was accumulated
against francisellosis in two species—Atlantic cod and tilapia—when immunized with
MVs isolated from Fnn and Fo, respectively. This lack of induced immunity is in stark
contrast to previously performed MV immunization experiments in olive flounder (Par-
alichthys olivaceus), rainbow trout (Oncorhynchus mykiss) or zebrafish (Danio rerio) [26,31,45].
Taken together, it is thus not possible to conclude that MVs would be reasonable vaccine
candidates against francisellosis in fish.
It would be interesting to explore further the induced and possibly suppressed path-
ways and gene regulations involved in the immune response to MVs in these different
hosts. It would also be especially interesting to understand the detailed differences between
the responses towards the respective pathogens in the respective warm and cold water
hosts, meaning that further in vivo studies should be conducted to unravel the factors that
determine the development of immunological memory in fish.
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 Figure A1. Immune genes with no significant differences in gene expression levels between the different treated groups
during the vaccine trial in tilapia. Gene expression levels of the investigated genes were analyzed by qPCR and are
displayed as log2 of relative gene expression. The gene expression levels were tested for significant differences in between
the treatments; (p < 0.05; one-way ANOVA with multiple comparison using Tukey test; error bars indicate mean ± SEM).
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